The NHS have published a 'Predict' tool that helps show how breast cancer treatments after surgery might improve survival rates.
Once details about the patient and their cancer have been entered, the tool will show how different treatments would be expected to improve survival rates up to 15 years after diagnosis. This is based on data from similar women in the past. It is important to note that these treatments have side effects which should also be considered when deciding on a treatment.
The tool is designed to be used by the patient and their doctor.
For more information see full article.
The tool applies to women who have had surgery for early invasive breast cancer and are deciding which other treatments to have. It is not designed for women who have had neo-adjuvant treatments (chemotherapy given before surgery) or have already been treated for cancer, for women whose breast cancer is in both breasts or has already spread to distant parts of the body at the time it is diagnosed or for women with non-invasive breast cancer, such as as Ductal Carcinoma In Situ or Lobular Carcinoma In Situ. It is also not designed for men with breast cancer.
The current version of the tool does not include all the treatments that are currently available. The NHS are working to include more in the near future. In the meantime, an appropriate clinician will be able to advise on all the treatment options suitable for a particular patient.
Predict only asks for certain information about the cancer. The inputs it asks for are the ones that we have enough information about to predict how they affect survival rates. It does not differentiate between the types of surgery (for example, mastectomy or lumpectomy) or ask for lifestyle factors such as smoking or exercise. These will affect survival, but at the moment we can't say by how much.
Contains public sector information licensed under the Open Government Licence v3.0.
NHS breast cancer Predict tool
Reporting of suspected adverse reactions
Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.